Click-based synthesis of triazolobithiazole Δf508-CFTR correctors for cystic fibrosis

Bioorganic and Medicinal Chemistry

Volumn 20, Issue 17, 2012, Pages 5247-5253

  Donald, Michael B ^a   Rodriguez, Kevin X ^a   Shay, Hannah ^a   Phuan, Puay Wah ^b   Verkman, A S ^b   Kurth, Mark J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CF corrector; CuAAC; Cystic fibrosis; Triazolobithiazole

Indexed keywords

1 [2 (5 CHLORO 2 METHOXYPHENYLAMINO) 4' METHYL 2' PIVAL AMIDO 4,5' BITHIAZOL 5 YL] 1H 1,2,3 TRIAZOL 4 CARBOXYLIC ACID; 1 [4 METHYL 2 (METHYLAMINO)THIAZOL 5 YL]ETHANONE; 5 (1H 1,2,3 TRIAZOL 1 YL) 4,5' BITHIAZOLE DERIVATIVE; METHYL 1 [1 BROMO 2 (4 METHYL 2 PIVALAMIDOTHIAZOL 5 YL) 2 OXOETHYL] 1H 1,2,3 TRIAZOLE 4 CARBOXYLATE; METHYL 1 [2 (4 METHYL 2 PIVALAMIDOTHIAZOL 5 YL) 2 OXOETHYL] 1H 1,2,3 TRIAZOLE 4 CARBOXYLATE; METHYL 1 [2 (5 CHLORO 2 METHOXYPHENYLAMINO) 4' METHYL 2' PIVALAMIDO 4,5' BITHIAZOL 5 YL] 1H 1,2,3 TRIAZOL 4 CARBOXYLATE; N (5 ACETYL 4 METHYLTHIAZOL 2 YL) N METHYLBENZAMIDE; N (5 ACETYL 4 METHYLTHIAZOL 2 YL)BENZAMIDE; N (5 ACETYL 4 METHYLTHIAZOL 2 YL)PIVALAMIDE; N [2 (5 CHLORO 2 METHOXYPHENYLAMINO) 4' METHYL 5 (4 PHENYL 1H 1,2,3 TRIAZOL 1 YL) 4,5' BITHIAZOL 2' YL]PIVALAMIDE; N [2 (ALLYLAMINO) 4' METHYL 5 (4 PHENYL 1H 1,2,3 TRIAZOL 1 YL) 4,5' BITHIAZOL 2' YL]PIVALAMIDE; N [2 AMINO 4' METHYL 5 (4 PHENYL 1H 1,2,3 TRIAZOL 1 YL) 4,5' BITHIAZOL 2'YL]PIVALAMIDE; N [4 METHYL 5 [ 2 (4 PHENYL 1H 1,2,3 TRIAZOL 1 YL)ACETYL]THIAZ OL 2 YL]PIVALAMIDE; N [4 METHYL 5 [ 2 [4 (MORPHOLINOMETHYL) 1H 1,2,3 TRIAZOL 1 YL]ACETYL] 4 METHYLTHIAZOL 2 YL]PIVALAMIDE; N [4 METHYL 5 [2 (4 PHENYL 1H 1,2,3 TRIAZOL 1 YL)ACETYL]THIAZ OL 2 YL BENZAMIDE]; N [4 METHYL 5 [2 [4 (MORPHOLINOMETHYL) 1H 1,2,3 TRIAZOL 1 YL]ACETYL] 4 METHOXYLTHIAZOL 2 YL]BENZAMIDE; N [4' METHYL 2 (METHYLAMINO)5 (4 PHENYL 1H 1,2,3 TRIAZOL 1 YL) 4,5' BITHIAZOL 2' YL]PIVALAMIDE; N [5 (2 BROMOACETYL) 4 METHYLTHIAZOL 2 YL]BENZAMIDE; N [5 (2 BROMOACETYL) 4 METHYLTHIAZOL 2 YL]PIVALAMIDE; N [5 [ 2 [4 (3 CYANOPROPYL) 1H 1,2,3 TRIAZOL 1 YL]ACETYL] 4 METHYLTHIAZOL 2 YL]PIVALAMIDE; N [5 [ 2 [4 (HYDROXYMETHYL) 1H 1,2,3 TRIAZOL 1 YL]ACETYL] 4 METHYLTHIAZOL 2 YL]PIVALAMIDE; N [5 [ 2 [4 (METHOXYMETHYL) 1H 1,2,3 TRIAZOL 1 YL]ACETYL] 4 METHYLTHIAZOL 2 YL]PIVALAMIDE; N [5 [ 2 [4 [(DIMETHYLAMINO)METHYL] 1H 1,2,3 TRIAZOL 1 YL]ACETYL] 4 METHYLTHIAZOL 2 YL]PIVALAMIDE; N [5 [2 [4 (3 HYDROXYPROPYL) 1H 1,2,3 TRIAZOL 1 YL]ACETYL] 4 METHYLTHIAZOL 2 YL]PIVALAMIDE; N [5 [2 [4 (4 CHLOROPHENYL) 1H 1,2,3 TRIAZOL 1 YL]ACETYL] 4 METHYLTHIAZOL 2 YL]PIVALAMIDE; N [5 [2 [4 (HYDROXYMETHYL) 1H 1,2,3 TRIAZOL 1 YL]ACETYL] 4 METHYLTHIAZOL 2 YL] N METHYLBENZAMIDE; N [5 [2 [4 (METHOXYMETHYL) 1H 1,2,3 TRIAZOL 1 YL]ACETYL] 4 METHOXYLTHIAZOL 2 YL]BENZAMIDE; N [5 [2 BROMO 2 [4 (HYDROXYMETHYL) 1H 1,2,3 TRIAZOL 1 YL]ACETYL] 4 METHYLTHIZOL 1 YL]PIVALAMIDE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BROMINATION; CLICK CHEMISTRY; CONTROLLED STUDY; CYCLOADDITION; CYSTIC FIBROSIS; DRUG ACTIVITY; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROPHILICITY; HYDROPHOBICITY; ONE POT SYNTHESIS; SAPONIFICATION;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TRIAZOLES;

EID: 84864984030     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2012.06.046     Document Type: Article

References (13)

1. J.L. Bobadilla, M. Macek, J.P. Fine, and P.M. Farrell Hum. Mutat. 19 2002 575
2. M. Sharma, M. Benharouga, W. Hu, and G.L. Lukacs J. Biol. Chem. 276 2001 8942
3. As reported by the cystic fibrosis foundation (http://www.cff.org/ treatments/Therapies/Kalydeco/), 'Kalydeco™ (generic name, ivacaftor; previously known as VX-770) is a new oral medication for the treatment of cystic fibrosis, approved by the US. Food and drug administration (FDA) in January 2012. The FDA approved Kalydeco for people ages 6 and older with the G551D mutation of CF'.
4. G. Yu, C.L. Yoo, B. Yang, M.W. Lodewyk, L. Meng, T.T. El-Idreesy, J.C. Fettinger, D.J. Tantillo, A.S. Verkman, and M.J. Kurth J. Med. Chem. 51 2008 6044
5. L. Ye, J.M. Knapp, P. Sangwung, J.C. Fettinger, A.S. Verkman, and M.J. Kurth J. Med. Chem. 53 2010 3772
6. S. Wang, C. Meades, G. Wood, A. Osnowski, S. Anderson, R. Yuill, M. Thomas, M. Mezna, W. Jackson, C. Midgley, G. Griffiths, I. Fleming, S. Green, I. McNae, S. Wu, C. McInnes, D. Zheleva, M.D. Walkinshaw, and P.M. Fischer J. Med. Chem. 47 2004 1662
7. P.S. Donnelly, S.D. Zanatta, S.C. Zammit, J.M. White, and S.J. Williams Chem. Commun. 2008 2459
8. A.R. Katritzky, J. Wu, L. Wrobel, S. Rachwal, and P.J. Steel Acta Chem. Scand. 1993 167
9. A. Hantzsch Justus Liebigs Ann. Chem. 250 1889 257
10. C.L. Yoo, G.J. Yu, B. Yang, L.I. Robins, A.S. Verkman, and M.J. Kurth Bioorg. Med. Chem. Lett. 18 2008 2610
11. H. Yang, A.A. Shelat, R.K. Guy, V.S. Gopinath, T. Ma, K. Du, G.L. Lukacs, A. Taddei, C. Folli, N. Pedemonte, L.J.V. Galietta, and A.S. Verkman J. Biol. Chem. 278 2003 35079
12. I. Malik, M.A. Sedlarova, C.S. Csollei, P. Andrianainty, P. Kurfurst, and J. Vanco Chem. Pap. 60 2006 42
13. A.K. Ghose, V.N. Viswanadhan, and J.J. Wendoloski J. Comb. Chem. 1 1999 55